BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36871200)

  • 21. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada.
    Godin A; Kronfli N; Cox J; Alary M; Maheu-Giroux M
    Int J Drug Policy; 2021 Feb; 88():102738. PubMed ID: 32278651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting.
    Lafferty L; Rance J; Dore GJ; Lloyd AR; Treloar C
    Addiction; 2021 May; 116(5):1162-1171. PubMed ID: 33006784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic Hepatitis C Cascade of Care in Prisoners-Is There Still Some Work to Do? Analysis of Two Large Penitentiaries in Northern Italy.
    Cambianica A; Marchese V; Pennati F; Faustinelli A; Migliorati M; Roda F; Spinetti A; Zaltron S; Fiorentini S; Caruso A; Quiros-Roldan E; Castelli F; Focà E
    Int J Environ Res Public Health; 2024 Jan; 21(1):. PubMed ID: 38248566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reducing barriers to the hepatitis C care cascade in prison via point-of-care RNA testing: a qualitative exploration of men in prison using an integrated framework.
    Lafferty L; Sheehan Y; Cochrane A; Grebely J; Lloyd AR; Treloar C
    Addiction; 2023 Jun; 118(6):1153-1160. PubMed ID: 36683132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era.
    Hariri S; Sharafi H; Sheikh M; Merat S; Hashemi F; Azimian F; Tamadoni B; Ramazani R; Gouya MM; Abbasi B; Tashakorian M; Alasvand R; Alavian SM; Poustchi H; Malekzadeh R
    Harm Reduct J; 2020 Oct; 17(1):80. PubMed ID: 33081794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C in Australian prisons: a national needs assessment.
    Mina MM; Herawati L; Butler T; Lloyd A
    Int J Prison Health; 2016; 12(1):3-16. PubMed ID: 26933988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An intervention to increase hepatitis C virus diagnosis and treatment uptake among people in custody in Iran.
    Hariri S; Alavi M; Roshandel G; Mohammadi Z; Fazel A; Amiriani T; Bazazan A; Motamed-Gorji N; Sohrabpour A; Merat S; Poustchi H; Malekzadeh R
    Int J Drug Policy; 2021 Sep; 95():103269. PubMed ID: 33991887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
    Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
    Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testing for hepatitis C virus infection in UK prisons: What actually happens?
    Jack K; Thomson BJ; Irving WL
    J Viral Hepat; 2019 Jun; 26(6):644-654. PubMed ID: 30702194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HCV spread among female incarcerated population and treatment pathways to viral elimination in Italian prison settings: clinical perspectives and medico legal aspects.
    Fiore V; Rastrelli E; Madeddu G; Ranieri R; De Vito A; Giuliani R; Di Mizio G; Bolcato M; De Matteis G; Ialungo AM; Dell'Isola S; Starnini G; Babudieri S
    BMC Infect Dis; 2022 Jul; 22(1):601. PubMed ID: 35799126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience.
    Winter RJ; Holmes JA; Papaluca TJ; Thompson AJ
    Viruses; 2022 Feb; 14(3):. PubMed ID: 35336905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of hepatitis C virus infection in the prison setting: The SToP-C study.
    Hajarizadeh B; Carson JM; Byrne M; Grebely J; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Lloyd AR; Dore GJ;
    J Viral Hepat; 2024 Jan; 31(1):21-34. PubMed ID: 37936544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel.
    Lafferty L; Rance J; Dore GJ; Grebely J; Lloyd AR; Treloar C;
    Int J Drug Policy; 2021 Dec; 98():103379. PubMed ID: 34311138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study.
    Stone J; Lim AG; Dore GJ; Borquez A; Geddes L; Gray R; Grebely J; Hajarizadeh B; Iversen J; Maher L; Valerio H; Martin NK; Hickman M; Lloyd AR; Vickerman P
    Liver Int; 2023 Mar; 43(3):569-579. PubMed ID: 36305315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mixed-methods evaluation of point-of-care hepatitis C virus RNA testing in a Scottish prison.
    Byrne CJ; Malaguti A; Inglis SK; Dillon JF
    BMJ Open; 2023 Apr; 13(4):e068604. PubMed ID: 37037621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
    Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
    Int J Drug Policy; 2023 Jan; 111():103917. PubMed ID: 36542883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Global State of Harm Reduction in Prisons.
    Sander G; Shirley-Beavan S; Stone K
    J Correct Health Care; 2019 Apr; 25(2):105-120. PubMed ID: 31084277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
    He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
    Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe.
    Stöver H; Meroueh F; Marco A; Keppler K; Saiz de la Hoya P; Littlewood R; Wright N; Nava F; Alam F; Walcher S; Somaini L
    BMC Public Health; 2019 Jan; 19(1):30. PubMed ID: 30621658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of HCV in prisons in Wales, UK and the impact of moving to opt-out HCV testing.
    Perrett SE; Plimmer A; Shankar AG; Craine N
    J Public Health (Oxf); 2020 May; 42(2):423-428. PubMed ID: 32090269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.